Bridgewater Associates LP Has $238,000 Position in Evolent Health, Inc. (NYSE:EVH)

Bridgewater Associates LP trimmed its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 70.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,118 shares of the technology company's stock after selling 51,380 shares during the quarter. Bridgewater Associates LP's holdings in Evolent Health were worth $238,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in EVH. Boston Partners grew its stake in shares of Evolent Health by 92.0% during the fourth quarter. Boston Partners now owns 2,444,006 shares of the technology company's stock worth $27,097,000 after acquiring an additional 1,171,304 shares during the last quarter. Norges Bank acquired a new stake in Evolent Health during the 4th quarter worth about $12,519,000. Barclays PLC lifted its holdings in Evolent Health by 234.4% in the fourth quarter. Barclays PLC now owns 915,422 shares of the technology company's stock valued at $10,298,000 after acquiring an additional 641,646 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Evolent Health by 90.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock worth $9,036,000 after buying an additional 380,790 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Evolent Health by 407.8% during the 4th quarter. Federated Hermes Inc. now owns 455,607 shares of the technology company's stock worth $5,126,000 after acquiring an additional 365,890 shares in the last quarter.

Insider Activity at Evolent Health

In other Evolent Health news, CEO Seth Blackley acquired 55,225 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average price of $9.01 per share, with a total value of $497,577.25. Following the transaction, the chief executive officer now owns 762,217 shares of the company's stock, valued at approximately $6,867,575.17. This trade represents a 7.81 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Diane Holder acquired 2,735 shares of Evolent Health stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $9.33 per share, with a total value of $25,517.55. Following the completion of the transaction, the director now directly owns 70,584 shares of the company's stock, valued at $658,548.72. This trade represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 74,000 shares of company stock valued at $666,315. Company insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on EVH. UBS Group cut their target price on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, January 16th. Canaccord Genuity Group lowered their price target on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. JPMorgan Chase & Co. lowered their price objective on Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday, March 10th. JMP Securities reiterated a "market outperform" rating and set a $12.00 price target on shares of Evolent Health in a research report on Friday, February 14th. Finally, Oppenheimer dropped their target price on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $17.64.

Evolent Health Stock Performance

EVH traded down $0.11 during trading on Friday, reaching $8.98. 1,960,800 shares of the company were exchanged, compared to its average volume of 2,344,855. Evolent Health, Inc. has a 52 week low of $8.35 and a 52 week high of $33.63. The stock has a market cap of $1.05 billion, a P/E ratio of -10.95 and a beta of 1.20. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm has a 50 day moving average of $9.53 and a 200 day moving average of $12.69.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. On average, sell-side analysts forecast that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.